Riptide Bioscience
Riptide Bioscience develops engineered peptides derived from host defense peptides found widely in nature. Riptide has developed an antimicrobial peptide, RP557, with extraordinary potential to address battlefield and complex traumatic wounds, both at the point of injury and during continuing care. RP557, once clinically translated will have the following favorable characteristics: • Broad spectrum antimicrobial activity thereby allowing empiric treatment, • Active against multidrug resistant organisms, including MRSA and P. aeruginosa, • Rapid bactericidal effect, • Less prone to pathogen resistance development, • Able to prevent biofilm formation, • Effective against established biofilm, • High Therapeutic Index, • Suppresses inflammatory responses (improves quality of healing; cosmesis and function), and • Accelerates wound healing.
Industries
Nr. of Employees
small (1-50)
Riptide Bioscience is currently seeking investment
Riptide Bioscience is seeking a investment in the range of
Patents
Products
Engineered peptide therapeutics for acute infection
Synthetic peptides derived from host-defense peptide structures designed for high-potency, broad-spectrum antimicrobial activity and biofilm penetration; intended for topical treatment of wounds, burns, and localized infections.
Engineered peptide therapeutics for inflammation modulation
Peptide candidates designed to moderate inflammatory responses and restore tissue balance in chronic inflammatory conditions.
Preclinical oncology peptide candidates
Designed lytic peptides with documented anticancer activity in preclinical studies intended for oncology indications.
Engineered peptide therapeutics for acute infection
Synthetic peptides derived from host-defense peptide structures designed for high-potency, broad-spectrum antimicrobial activity and biofilm penetration; intended for topical treatment of wounds, burns, and localized infections.
Engineered peptide therapeutics for inflammation modulation
Peptide candidates designed to moderate inflammatory responses and restore tissue balance in chronic inflammatory conditions.
Preclinical oncology peptide candidates
Designed lytic peptides with documented anticancer activity in preclinical studies intended for oncology indications.
Expertise Areas
- Peptide therapeutic development
- Antimicrobial therapeutics
- Anti-inflammatory therapeutics
- Oncology therapeutics (peptide-based)
Key Technologies
- Synthetic peptide design and optimization
- Membrane-targeting antimicrobial mechanism
- Biofilm penetration assays
- In vitro antimicrobial and anticancer assays
Key People
Charles Garvin
CEO
Dr. Jesse Jaynes
Principal Scientist
Dr. L. Edward Clemens
VP Program Management & Principal Scientist
Dr. Henry Lopez
EVP
Dr. Kathryn Woodburn
Sr VP, Translational Sciences
Charles Garvin
CEO
Dr. Jesse Jaynes
Principal Scientist
Dr. L. Edward Clemens
VP Program Management & Principal Scientist
Dr. Henry Lopez
EVP
Dr. Kathryn Woodburn
Sr VP, Translational Sciences
News & Updates
Received the highest award at the Military Health Systems Research Symposium for antimicrobial research.
Study demonstrated the use of radiolabeled peptides for PET imaging of tumor-associated macrophages in a colon cancer model.
CD206-targeted peptide compared favorably with FDA-approved antifibrotic therapies in mouse models.
Peer-reviewed publication reports on efficacy of an engineered peptide in a mouse model for diabetic wound healing.
Science Translational Medicine article establishes CD206 as a novel immune checkpoint for modulating macrophages.
Antimicrobial peptides effectively treated antibiotic-resistant acne vulgaris in preclinical testing.
Received the highest award at the Military Health Systems Research Symposium for antimicrobial research.
Study demonstrated the use of radiolabeled peptides for PET imaging of tumor-associated macrophages in a colon cancer model.
CD206-targeted peptide compared favorably with FDA-approved antifibrotic therapies in mouse models.
Peer-reviewed publication reports on efficacy of an engineered peptide in a mouse model for diabetic wound healing.
Science Translational Medicine article establishes CD206 as a novel immune checkpoint for modulating macrophages.
Antimicrobial peptides effectively treated antibiotic-resistant acne vulgaris in preclinical testing.